<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01077960</url>
  </required_header>
  <id_info>
    <org_study_id>25373 (NCT01077960)</org_study_id>
    <nct_id>NCT01077960</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of Serostim® Human Immunodeficiency Virus-Associated Adipose Redistribution Syndrome</brief_title>
  <official_title>Phase III, Multi-Center, Open, 12-Week, Follow-up Safety and Efficacy Study of Serostim® in Subjects With Human Immunodeficiency Virus-Associated Adipose Redistribution Syndrome (HARS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EMD Serono</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>EMD Serono</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In Serono Study 24380, the antecedent protocol to Study 25373, patients were randomly
      assigned in a 3.0-to-1.0 ratio to Groups A and B. All patients in Group A received
      recombinant human growth hormone (Serostim®) 4 mg daily (the &quot;induction&quot; phase) for the first
      12 weeks, and then were re-randomized to receive either placebo or Serostim 2 mg on alternate
      days (roughly equivalent to 1 mg daily) during Weeks 12-36 (the &quot;maintenance&quot; phase). All
      patients in Group B initially received placebo from baseline to Week 24, and then received
      Serostim® 4 mg daily from Weeks 24 to 36 (Grunfeld, 2007).

      In the follow-up Study 25373, any subject who was enrolled in Serono Study 24380 and was
      assigned to Group A, who fully completed all study visits without a major protocol violation,
      was eligible to enroll to receive re-treatment with Serostim at a dose of 4 mg daily for 12
      weeks. During study 25373, safety was monitored by recording of adverse events and
      measurement of urinalysis and laboratory blood tests to assess fasting glucose, fasting
      insulin, and routine biochemistry and hematology parameters. At Week 12 or at the time of
      study termination, subjects underwent re-assessment of body composition via anthropometry
      measurements and dual photon absorptiometry (DXA) scanning. In addition, at study
      termination, measurements of insulin-like growth factor I (IGF-I), insulin-like growth
      binding protein 3 (IGFBP-3), fasting lipid profile, and oral glucose tolerance testing were
      obtained.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2005</start_date>
  <completion_date type="Actual">January 2006</completion_date>
  <primary_completion_date type="Actual">January 2006</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline to Week 12 in Trunk Fat as Assessed by Dual-Energy X-Ray Absorptiometry (DXA) Scan</measure>
    <time_frame>baseline to 12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 12 in Waist Circumference</measure>
    <time_frame>baseline to 12 weeks</time_frame>
    <description>Measured by anthropometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 12 in Insulin-like Growth Factor I</measure>
    <time_frame>baseline to 12 weeks</time_frame>
    <description>Circulating levels of IGF-I</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oral Glucose Tolerance Testing - Change From Baseline to Week 12 in Fasting Insulin</measure>
    <time_frame>baseline to 12 weeks</time_frame>
    <description>Oral glucose tolerance testing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oral Glucose Tolerance Testing - Change From Baseline to Week 12 in 120 Minute Glucose</measure>
    <time_frame>baseline to 12 weeks</time_frame>
    <description>Oral glucose testing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oral Glucose Tolerance Testing - Change From Baseline to Week 12 in Fasting Glucose</measure>
    <time_frame>baseline to 12 weeks</time_frame>
    <description>Oral glucose testing</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">126</enrollment>
  <condition>Human Immunodeficiency Virus-Associated Adipose Redistribution Syndrome</condition>
  <arm_group>
    <arm_group_label>Serostim</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Serostim® 4 mg daily given for 12 weeks (following a prior 36-week treatment [Serono Study 24380] with Serostim® 4 mg daily given for 12 weeks, followed by 24-weeks of either Serostim® 2 mg every other day or Placebo every other day)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Serostim</intervention_name>
    <description>Serostim® 4 mg daily given for 12 weeks (following a prior 36-week treatment [Serono Study 24380] with Serostim® 4 mg daily given for 12 weeks, followed by 24-weeks of either Serostim® 2 mg every other day or Placebo every other day)</description>
    <arm_group_label>Serostim</arm_group_label>
    <other_name>mammalian cell-derived recombinant human growth hormone</other_name>
    <other_name>r hGH</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must meet all inclusion/exclusion criteria for Serono Study 25373, have participated
             in Serono Study 24380, must have been assigned to Group A, must have completed all
             treatments and procedures (including baseline, Week 12 and Week 36 Computerized
             Tomography (CT) and Dual-Energy X-ray Absorptiometry (DXA) Scans) and had no major
             protocol violation.

          -  Must be taking antiretroviral medications that are approved or are available under a
             Treatment Investigational New Drug (IND). Subjects must also agree not to discontinue
             or to change their regimen for the duration of the study except as judged medically
             necessary.

          -  Must be willing and able to comply with the protocol for the duration of the study.

          -  Must have voluntarily provided written informed consent and a subject authorization
             under Health Insurance Portability and Accountability Act of 1996 (HIPAA), prior to
             any study-related procedure that is not part of normal medical care, and with the
             understanding that the subject may withdraw consent at any time without prejudice to
             future medical care.

          -  If female, subjects must either:

               -  Be post menopausal (=/&gt;1 year) or surgically sterilized (i.e., have undergone
                  tubal ligation or hysterectomy), or

               -  Use a contraceptive method for the duration of the study such as: hormonal
                  contraceptive,intra uterine device,diaphragm with spermicide, or condom with
                  spermicide, and

               -  Must be neither pregnant nor breast feeding.

               -  Confirmation that female subjects of childbearing potential are not pregnant must
                  be established by a negative pregnancy test prior to initiating first treatment.

        A pregnancy test is not required if the subject is post menopausal or surgically
        sterilized.

        Exclusion Criteria:

          -  Have any condition, which interferes with informed consent or protocol compliance
             including, but not limited to, active substance abuse and/or dementia.

          -  Have any active malignancy, except localized cutaneous Kaposi's sarcoma (fewer than 10
             lesions, none of which are larger than 2 cm, and not on active therapy).

          -  Have active central nervous system (CNS) process associated with neurological
             findings.

          -  Have acute illness treated in an intensive care unit, e.g., due to complications
             following open heart or abdominal surgery, multiple accidental trauma, or acute
             respiratory failure.

          -  Have any medical condition in view of which the study doctor and/or Serono
             Medical/Therapeutic Director feels that it would be in the best interest of the
             subject not to participate in the follow-up study.

          -  Are unable to comply with the Concomitant Therapy restrictions as outlined in Section
             5.5 and listed as follows:

               -  Therapy for obesity including therapy with anorexigenic or fat reducing drugs.

               -  Anti-diabetic or insulin sensitizing medications.

               -  Systemic glucocorticoids.

               -  Systemic chemotherapy, interferon or radiation therapy treatment.

               -  Androgenic agents including, but not limited to, testosterone, nandrolone
                  (Deca-durabolin), oxandrolone (Oxandrin), oxymetholone (Anadrol),
                  dehydroepiandrosterone (DHEA), etc. (Testosterone replacement therapy for
                  hypogonadism is the exception to this exclusion and will be allowed if started
                  &gt;30 days prior to Study Day 1 of Serono Study 24380).

               -  Progestational agents, unless used for oral contraception or post-menopausal
                  hormone replacement therapy.

               -  Appetite stimulants such as dronabinol (Marinol), megestrol acetate (Megace), or
                  cyproheptadine (Periactin).

               -  Investigational agents, unless approved in advance by Serono's Medical Director.
                  Specifically, experimental antiretroviral agents are disallowed, unless available
                  under a treatment IND or expanded access program (30 days).

               -  Liposuction or other elective plastic surgery.

               -  Acquired Immune Deficiency Syndrome (AIDS) wasting therapy with growth hormone
                  and/or prior treatment with growth hormone or a growth hormone releasing factor
                  (for 12 months prior to the screening visit).

          -  Are participating in any other clinical studies (except Serono Study 24380).
             Observation studies are allowed, but prior written permission by Serono
             Medical/Therapeutic Director must be granted.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Alabama/Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Care Clinic</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Practice</name>
      <address>
        <city>Palm Beach</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSD - AVRC (AntiViralResearchCenter)</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harbor-UCLA Medical Center</name>
      <address>
        <city>Torrence</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AIDS Alliance</name>
      <address>
        <city>West Hollywood</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Circle Medical LLC</name>
      <address>
        <city>Norwalk</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Practice</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Practice</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Care Resources</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Practice</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Practice</name>
      <address>
        <city>North Miami Beach</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Infectious Disease Associates</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AIDS Research Consortium of Atlanta</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Community Research Initiative of New England</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tufts University School of Medicine</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hennepin County Medical Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Luke's Roosevelt Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincents Catholic Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weill Medical College of Cornell University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Texas Clinical Research</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IPD Research</name>
      <address>
        <city>Annandale</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Practice</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Paul Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Grunfeld C, Thompson M, Brown SJ, Richmond G, Lee D, Muurahainen N, Kotler DP; Study 24380 Investigators Group. Recombinant human growth hormone to treat HIV-associated adipose redistribution syndrome: 12 week induction and 24-week maintenance therapy. J Acquir Immune Defic Syndr. 2007 Jul 1;45(3):286-97.</citation>
    <PMID>17592343</PMID>
  </reference>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 26, 2010</study_first_submitted>
  <study_first_submitted_qc>February 26, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 1, 2010</study_first_posted>
  <results_first_submitted>May 25, 2010</results_first_submitted>
  <results_first_submitted_qc>May 25, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 23, 2010</results_first_posted>
  <last_update_submitted>August 4, 2013</last_update_submitted>
  <last_update_submitted_qc>August 4, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 7, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Serostim</keyword>
  <keyword>HARS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Study Initiation Date: 03 Feb 2005 (date of first subject, first dose) Study Completion Date 04 Jan 2006 (date of last subject, last visit) 26 study centers in the United States and British Columbia participated in this study, with each center enrolling at least one subject into the study.</recruitment_details>
      <pre_assignment_details>Any subject who was enrolled in Serono Study 24380, assigned to Group A, and fully completed all study visits without major protocol violations was to be allowed to enroll in Study 25373</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Serostim</title>
          <description>Serostim® 4 mg daily given for 12 weeks (following a prior 36-week treatment [Serono Study 24380] with Serostim® 4 mg daily given for 12 weeks, followed by 24-weeks of either Serostim® 2 mg every other day or Placebo every other day)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="126">130 subjects consented to participate, 129 enrolled in the study, and 126 received study drug</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="110">Modified Intent To Treat (ITT) Population</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Reason unspecified</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Serostim</title>
          <description>Serostim® 4 mg daily given for 12 weeks (following a prior 36-week treatment [Serono Study 24380] with Serostim® 4 mg daily given for 12 weeks, followed by 24-weeks of either Serostim® 2 mg every other day or Placebo every other day)</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="126"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="126"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45.4" spread="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="113"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="125"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Insulin-like Growth Factor I</title>
          <description>n=112</description>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="242.6" spread="132.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Oral Glucose Tolerance Testing - 120 Minute Glucose</title>
          <description>n=105</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="102.3" spread="35.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Oral Glucose Tolerance Testing - Fasting Glucose</title>
          <description>n=124</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="94.5" spread="14.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Oral Glucose Tolerance Testing - Fasting Insulin</title>
          <description>n=111</description>
          <units>mcIU/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11.4" spread="13.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Trunk Fat</title>
          <description>n=106</description>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10.4" spread="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Waist Circumference</title>
          <description>N=116</description>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="97.3" spread="9.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline to Week 12 in Trunk Fat as Assessed by Dual-Energy X-Ray Absorptiometry (DXA) Scan</title>
        <time_frame>baseline to 12 weeks</time_frame>
        <population>The analysis population reported here comprised the subjects who received at least one dose of study drug</population>
        <group_list>
          <group group_id="O1">
            <title>Serostim</title>
            <description>Serostim® 4 mg daily given for 12 weeks (following a prior 36-week treatment [Serono Study 24380] with Serostim® 4 mg daily given for 12 weeks, followed by 24-weeks of either Serostim® 2 mg every other day or Placebo every other day)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 12 in Trunk Fat as Assessed by Dual-Energy X-Ray Absorptiometry (DXA) Scan</title>
          <population>The analysis population reported here comprised the subjects who received at least one dose of study drug</population>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.7" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 12 in Waist Circumference</title>
        <description>Measured by anthropometry</description>
        <time_frame>baseline to 12 weeks</time_frame>
        <population>The analysis population reported here comprised the subjects who received at least one dose of study drug</population>
        <group_list>
          <group group_id="O1">
            <title>Serostim</title>
            <description>Serostim® 4 mg daily given for 12 weeks (following a prior 36-week treatment [Serono Study 24380] with Serostim® 4 mg daily given for 12 weeks, followed by 24-weeks of either Serostim® 2 mg every other day or Placebo every other day)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 12 in Waist Circumference</title>
          <description>Measured by anthropometry</description>
          <population>The analysis population reported here comprised the subjects who received at least one dose of study drug</population>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="116"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.5" spread="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 12 in Insulin-like Growth Factor I</title>
        <description>Circulating levels of IGF-I</description>
        <time_frame>baseline to 12 weeks</time_frame>
        <population>The analysis population reported here comprised the subjects who received at least one dose of study drug</population>
        <group_list>
          <group group_id="O1">
            <title>Serostim</title>
            <description>Serostim® 4 mg daily given for 12 weeks (following a prior 36-week treatment [Serono Study 24380] with Serostim® 4 mg daily given for 12 weeks, followed by 24-weeks of either Serostim® 2 mg every other day or Placebo every other day)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 12 in Insulin-like Growth Factor I</title>
          <description>Circulating levels of IGF-I</description>
          <population>The analysis population reported here comprised the subjects who received at least one dose of study drug</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="135.7" spread="210.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Oral Glucose Tolerance Testing - Change From Baseline to Week 12 in Fasting Insulin</title>
        <description>Oral glucose tolerance testing</description>
        <time_frame>baseline to 12 weeks</time_frame>
        <population>The analysis population reported here comprised the subjects who received at least one dose of study drug</population>
        <group_list>
          <group group_id="O1">
            <title>Serostim</title>
            <description>Serostim® 4 mg daily given for 12 weeks (following a prior 36-week treatment [Serono Study 24380] with Serostim® 4 mg daily given for 12 weeks, followed by 24-weeks of either Serostim® 2 mg every other day or Placebo every other day)</description>
          </group>
        </group_list>
        <measure>
          <title>Oral Glucose Tolerance Testing - Change From Baseline to Week 12 in Fasting Insulin</title>
          <description>Oral glucose tolerance testing</description>
          <population>The analysis population reported here comprised the subjects who received at least one dose of study drug</population>
          <units>mcIU/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="111"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.8" spread="22.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Oral Glucose Tolerance Testing - Change From Baseline to Week 12 in 120 Minute Glucose</title>
        <description>Oral glucose testing</description>
        <time_frame>baseline to 12 weeks</time_frame>
        <population>The analysis population reported here comprised the subjects who received at least one dose of study drug</population>
        <group_list>
          <group group_id="O1">
            <title>Serostim</title>
            <description>Serostim® 4 mg daily given for 12 weeks (following a prior 36-week treatment [Serono Study 24380] with Serostim® 4 mg daily given for 12 weeks, followed by 24-weeks of either Serostim® 2 mg every other day or Placebo every other day)</description>
          </group>
        </group_list>
        <measure>
          <title>Oral Glucose Tolerance Testing - Change From Baseline to Week 12 in 120 Minute Glucose</title>
          <description>Oral glucose testing</description>
          <population>The analysis population reported here comprised the subjects who received at least one dose of study drug</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.7" spread="43.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.007</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Oral Glucose Tolerance Testing - Change From Baseline to Week 12 in Fasting Glucose</title>
        <description>Oral glucose testing</description>
        <time_frame>baseline to 12 weeks</time_frame>
        <population>The analysis population reported here comprised the subjects who received at least one dose of study drug</population>
        <group_list>
          <group group_id="O1">
            <title>Serostim</title>
            <description>Serostim® 4 mg daily given for 12 weeks (following a prior 36-week treatment [Serono Study 24380] with Serostim® 4 mg daily given for 12 weeks, followed by 24-weeks of either Serostim® 2 mg every other day or Placebo every other day)</description>
          </group>
        </group_list>
        <measure>
          <title>Oral Glucose Tolerance Testing - Change From Baseline to Week 12 in Fasting Glucose</title>
          <description>Oral glucose testing</description>
          <population>The analysis population reported here comprised the subjects who received at least one dose of study drug</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="124"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.5" spread="20.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.015</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were to be reported and collected on an ongoing basis from the day of written informed consent (baseline) until 4 weeks after the last investigational product administration.</time_frame>
      <desc>Adverse events occurring during study treatment are reported</desc>
      <group_list>
        <group group_id="E1">
          <title>Serostim</title>
          <description>Serostim® 4 mg daily given for 12 weeks (following a prior 36-week treatment [Serono Study 24380] with Serostim® 4 mg daily given for 12 weeks, followed by 24-weeks of either Serostim® 2 mg every other day or Placebo every other day)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (8.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (8.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="89" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="47" subjects_affected="31" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="30" subjects_affected="21" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Joint swelling</sub_title>
                <counts group_id="E1" events="11" subjects_affected="8" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Musculoskeletal stiffness</sub_title>
                <counts group_id="E1" events="10" subjects_affected="7" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>EMD Serono Medical Information</name_or_title>
      <organization>EMD Serono</organization>
      <phone>1-888-ASK-SERO (275-7376)</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

